Since the Rgs2 null mouse was developed in the C57Bl/6 background, we injected Rgs2−/− mice and C57BL/6 wild type controls with syngeneic 3LL cells subcutaneously in the hindlimb, and measured tumor growth over time. The gene discussed is RGS2; the disease is neoplasm.